Compass Therapeutics, Inc. (CMPX): Revenue

Annual figures by period end, from SEC filings.

Year ended 2025-12-31

2023-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$0	-100.0%	2026-03-05, From 2025-01-01
2024-12-31	$850.0K	n/a	2026-03-05, From 2024-01-01
2023-12-31	$0	n/a	2025-02-27, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Compass Therapeutics, Inc. (CMPX)	2025-12-31	$0	-100.0%
Vaxart, Inc. (VXRT)	2025-12-31	$237.26M	+726.7%
Amgen Inc (AMGN)	2025-12-31	$36.75B	+10.0%
Repligen Corp (RGEN)	2025-12-31	$738.26M	+16.4%
Champions Oncology, Inc. (CSBR)	2026-04-30	$59.42M	+4.4%
Bio-Techne Corp (TECH)	2026-06-30	$1.22B	-0.4%
Biogen Inc. (BIIB)	2025-12-31	$9.89B	+2.2%
Lineage Cell Therapeutics, Inc. (LCTX)	2025-12-31	$14.56M	+53.2%
Gilead Sciences, Inc. (GILD)	2025-12-31	$29.44B	+2.4%

Compare CMPX, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗